FDA Clears Medtronic’s CRRT System For Pediatric Kidney Disease
The de novo clearance makes the Carpediem system the first commercially available system indicated for continuous renal replacement therapy in pediatric patients.
You may also be interested in...
The pandemic may accelerate a move toward versatile, single-solution renal replacement therapy in intensive care.
Medtronic PLC is expanding its presence in the end-stage renal disease device market with the acquisition of hemodialysis company Bellco Health Corp.
Reuters reported that global private equity firm Carlyle Group has offered to pay at least $7bn for Medtronic’s patient monitoring and respiratory interventions businesses. Medtronic announced its plan to get out of those businesses about one year ago.